About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 838491, 21 pages
http://dx.doi.org/10.1155/2013/838491
Review Article

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, 20132 Milano, Italy

Received 10 May 2013; Revised 5 July 2013; Accepted 11 July 2013

Academic Editor: Aldo Manzin

Copyright © 2013 Giuseppe Sautto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Cleton, M. Koopmans, J. Reimerink, G. J. Godeke, and C. Reusken, “Come fly with me: review of clinically important arboviruses for global travelers,” Journal of Clinical Virology, vol. 55, no. 3, pp. 191–203, 2012.
  2. F. X. Heinz, H. Holzmann, A. Essl, and M. Kundi, “Field effectiveness of vaccination against tick-borne encephalitis,” Vaccine, vol. 25, no. 43, pp. 7559–7567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Barrett and D. E. Teuwen, “Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place?” Current Opinion in Immunology, vol. 21, no. 3, pp. 308–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. B. Halstead and S. J. Thomas, “New vaccines for Japanese encephalitis,” Current Infectious Disease Reports, vol. 12, no. 3, pp. 174–180, 2010.
  5. R. Burioni, M. Perotti, N. Mancini, and M. Clementi, “Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs,” Journal of Hepatology, vol. 49, no. 2, pp. 299–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Diotti, G. A. Sautto, L. Solforosi, N. Mancini, M. Clementi, and R. Burioni, “Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein,” New Microbiologica, vol. 35, no. 4, pp. 475–479, 2012.
  7. R. Burioni, F. Canducci, N. Mancini et al., “Molecular cloning of the first human monoclona antibodies neutralizing with high potency Swine-origin Influenza A pandemic virus (S-OIV),” New Microbiologica, vol. 32, no. 4, pp. 319–324, 2009. View at Scopus
  8. P. K. Chandra, S. Hazari, B. Poat et al., “Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone,” Virology Journal, vol. 7, article 118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Clementi, D. de Marco, N. Mancini et al., “A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes,” PLoS ONE, vol. 6, no. 12, Article ID e28001, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. de Marco, N. Clementi, N. Mancini et al., “A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses,” PLoS ONE, vol. 7, no. 4, Article ID e34415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Solforosi, N. Mancini, F. Canducci et al., “A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments,” New Microbiologica, vol. 35, no. 3, pp. 289–294, 2012.
  12. E. V. Koonin and V. V. Dolja, “Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences,” Critical Reviews in Biochemistry and Molecular Biology, vol. 28, no. 5, pp. 375–430, 1993. View at Scopus
  13. J. S. Mackenzie, D. J. Gubler, and L. R. Petersen, “Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses,” Nature Medicine, vol. 10, no. 12, pp. S98–S109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. T. J. Smith, W. E. Brandt, J. L. Swanson, J. M. McCown, and E. L. Buescher, “Physical and biological properties of dengue-2 virus and associated antigens,” Journal of Virology, vol. 5, no. 4, pp. 524–532, 1970. View at Scopus
  15. J. M. Smit, B. Moesker, I. Rodenhuis-Zybert, and J. Wilschut, “Flavivirus cell entry and membrane fusion,” Viruses, vol. 3, no. 2, pp. 160–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Kuhn, W. Zhang, M. G. Rossmann et al., “Structure of dengue virus: implications for flavivirus organization, maturation, and fusion,” Cell, vol. 108, no. 5, pp. 717–725, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Stiasny, J. H. Aberle, M. Keller, B. Grubeck-Loebenstein, and F. X. Heinz, “Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis,” PLoS ONE, vol. 7, no. 3, Article ID e34145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Thomas, O. Verlaeten, A. Cabié et al., “Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic,” American Journal of Tropical Medicine and Hygiene, vol. 78, no. 6, pp. 990–998, 2008. View at Scopus
  19. Y. Zhang, J. Corver, P. R. Chipman et al., “Structures of immature flavivirus particles,” EMBO Journal, vol. 22, no. 11, pp. 2604–2613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. K. I. Falconar, “Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins,” Archives of Virology, vol. 144, no. 12, pp. 2313–2330, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. K.-J. Huang, Y.-C. Yang, Y.-S. Lin et al., “The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection,” Journal of Immunology, vol. 176, no. 5, pp. 2825–2832, 2006. View at Scopus
  22. A. K. I. Falconar, “Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design,” Clinical and Vaccine Immunology, vol. 14, no. 5, pp. 493–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. W. Mandl, F. Guirakhoo, H. Holzmann, F. X. Heinz, and C. Kunz, “Antigenic structure of the flavivirus envelope protein E at the molecular level, using the tick-borne encephalitis virus as a model,” Journal of Virology, vol. 63, no. 2, pp. 564–571, 1989. View at Scopus
  24. F. A. Rey, F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison, “The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution,” Nature, vol. 375, no. 6529, pp. 291–298, 1995. View at Scopus
  25. S. L. Allison, K. Stiasny, K. Stadler, C. W. Mandl, and F. X. Heinz, “Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E,” Journal of Virology, vol. 73, no. 7, pp. 5605–5612, 1999. View at Scopus
  26. D. E. Klein, J. L. Choi, and S. C. Harrison, “Structure of a dengue virus envelope protein late-stage fusion intermediate,” Journal of Virology, vol. 87, no. 4, pp. 2287–2293, 2013.
  27. S. L. Hanna, T. C. Pierson, M. D. Sanchez, A. A. Ahmed, M. M. Murtadha, and R. W. Doms, “N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity,” Journal of Virology, vol. 79, no. 21, pp. 13262–13274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Mancini, G. Sautto, N. Clementi et al., “Neutralization interfering antibodies: a, “novel” example of humoral immune dysfunction facilitating viral escape?” Viruses, vol. 4, no. 9, pp. 1731–1752, 2012.
  29. Y. Modis, S. Ogata, D. Clements, and S. C. Harrison, “Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein,” Journal of Virology, vol. 79, no. 2, pp. 1223–1231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Miller, “Recent progress in dengue vaccine research and development,” Current Opinion in Molecular Therapeutics, vol. 12, no. 1, pp. 31–38, 2010.
  31. J. H. Chávez, J. R. Silva, A. A. Amarilla, and L. T. Moraes Figueiredo, “Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization,” Biologicals, vol. 38, no. 6, pp. 613–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Shrestha, J. D. Brien, S. Sukupolvi-Petty et al., “The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1,” PLoS Pathogens, vol. 6, no. 4, Article ID e1000823, 2010. View at Scopus
  33. G. D. Gromowski, N. D. Barrett, and A. D. T. Barrett, “Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus,” Journal of Virology, vol. 82, no. 17, pp. 8828–8837, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Sukupolvi-Petty, S. K. Austin, W. E. Purtha et al., “Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes,” Journal of Virology, vol. 81, no. 23, pp. 12816–12826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Sukupolvi-Petty, S. K. Austin, M. Engle et al., “Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2,” Journal of Virology, vol. 84, no. 18, pp. 9227–9239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y.-Q. Deng, J.-X. Dai, G.-H. Ji et al., “A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of e protein,” PLoS ONE, vol. 6, no. 1, Article ID e16059, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Costin, E. Zaitseva, K. M. Kahle et al., “Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop,” Journal of Virology, vol. 87, no. 1, pp. 52–66, 2013.
  38. C. M. Midgley, A. Flanagan, H. B. Tran et al., “Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity,” Journal of Immunology, vol. 188, no. 10, pp. 4971–4979, 2012.
  39. N. J. Moreland, P. Susanto, E. Lim et al., “Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries,” International Journal of Molecular Sciences, vol. 13, no. 3, pp. 2618–2635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. J. B. Cockburn, M. E. Navarro Sanchez, N. Fretes et al., “Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody,” Structure, vol. 20, no. 2, pp. 303–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Rajamanonmani, C. Nkenfou, P. Clancy et al., “On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes,” Journal of General Virology, vol. 90, no. 4, pp. 799–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. L. H. Gould, J. Sui, H. Foellmer et al., “Protective and herapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus,” Journal of Virology, vol. 79, no. 23, pp. 14606–14613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Sultana, H. G. Foellmer, G. Neelakanta et al., “Fusion Loop Peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody,” Journal of Immunology, vol. 183, no. 1, pp. 650–660, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Oliphant, M. Engle, G. E. Nybakken et al., “Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus,” Nature Medicine, vol. 11, no. 5, pp. 522–530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. G. E. Nybakken, T. Oliphant, S. Johnson, S. Burke, M. S. Diamond, and D. H. Fremont, “Structural basis of West Nile virus neutralization by a therapeutic antibody,” Nature, vol. 437, no. 7059, pp. 764–769, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. G. D. Gromowski, J. T. Roehrig, M. S. Diamond, J. C. Lee, T. J. Pitcher, and A. D. T. Barrett, “Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape,” Virology, vol. 407, no. 2, pp. 237–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. T. Roehrig, R. A. Bolin, and R. G. Kelly, “Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica,” Virology, vol. 246, no. 2, pp. 317–328, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. R. de Alwis, S. A. Smith, N. P. Olivarez et al., “Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7439–7444, 2012.
  49. S. K. Austin, K. A. Dowd, B. Shrestha et al., “Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope,” PLoS Pathogens, vol. 8, no. 10, Article ID e1002930, 2012.
  50. M. Throsby, C. Geuijen, J. Goudsmit et al., “Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus,” Journal of Virology, vol. 80, no. 14, pp. 6982–6992, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. P. Goncalvez, R. H. Purcell, and C.-J. Lai, “Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein,” Journal of Virology, vol. 78, no. 23, pp. 12919–12928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. J. T. Roehrig, J. H. Mathews, and D. W. Trent, “Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies,” Virology, vol. 128, no. 1, pp. 118–126, 1983. View at Scopus
  53. J. T. Roehrig, L. A. Staudinger, A. R. Hunt, J. H. Mathews, and C. D. Blair, “Antibody prophylaxis and therapy for flavivirus encephalitis infections,” Annals of the New York Academy of Sciences, vol. 951, pp. 286–297, 2001. View at Scopus
  54. A. P. Goncalvez, C.-H. Chien, K. Tubthong et al., “Humanized monoclonal antibodies derived from chimpanzee fabs protect against Japanese encephalitis virus in vitro and in vivo,” Journal of Virology, vol. 82, no. 14, pp. 7009–7021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Arakawa, T. Yamashiro, G.-I. Uechi, M. Tadano, and A. Nishizono, “Construction of human Fab (γ1/κ) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus,” Microbiology and Immunology, vol. 51, no. 6, pp. 617–625, 2007. View at Scopus
  56. L. Warter, C. Y. Lee, R. Thiagarajan et al., “Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency,” Journal of Immunology, vol. 186, no. 5, pp. 3258–3264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Pal, K. A. Dowd, J. D. Brien et al., “Development of a highly protective combination monoclonal antibody therapy against chikungunya virus,” PLoS Pathogens, vol. 9, no. 4, Article ID e1003312, 2013.
  58. A. Bertolotti-Ciarlet, J. Smith, K. Strecker et al., “Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins,” Journal of Virology, vol. 79, no. 10, pp. 6152–6161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. J. K. Battles and J. M. Dalrymple, “Genetic variation among geographic isolates of Rift Valley fever virus,” American Journal of Tropical Medicine and Hygiene, vol. 39, no. 6, pp. 617–631, 1988. View at Scopus
  60. B. A. Thibodeaux, N. C. Garbino, N. M. Liss et al., “A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model,” Antiviral Research, vol. 94, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Daffis, R. E. Kontermann, J. Korimbocus, H. Zeller, H.-D. Klenk, and J. Ter Meulen, “Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants,” Virology, vol. 337, no. 2, pp. 262–272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. L. N. Levanov, L. E. Matveev, E. P. Goncharova et al., “Chimeric antibodies against tick-borne encephalitis virus,” Vaccine, vol. 28, no. 32, pp. 5265–5271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. A. R. Hunt, S. Frederickson, C. Hinkel, K. S. Bowdish, and J. T. Roehrig, “A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus,” Journal of General Virology, vol. 87, no. 9, pp. 2467–2476, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. J. M. da Silva Voorham, I. A. Rodenhuis-Zybert, N. V. A. Nuñez et al., “Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2,” PLoS ONE, vol. 7, no. 3, Article ID e29957, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. T. C. Pierson, Q. Xu, S. Nelson et al., “The stoichiometry of antibody-mediated neutralization and enhancement of west nile virus infection,” Cell Host and Microbe, vol. 1, no. 2, pp. 135–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Sautto, N. Mancini, R. A. Diotti, L. Solforosi, M. Clementi, and R. Burioni, “Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference,” Antiviral Research, vol. 96, no. 1, pp. 82–89, 2012.
  67. R. Burioni, Y. Matsuura, N. Mancini et al., “Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype,” Journal of Virology, vol. 76, no. 22, pp. 11775–11779, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. R. J. Phillpotts, J. R. Stephenson, and J. S. Porterfield, “Antibody-dependent enhancement of tick-borne encephalitus virus infectivity,” Journal of General Virology, vol. 66, no. 8, pp. 1831–1837, 1985. View at Scopus
  69. K. A. Dowd and T. C. Pierson, “Antibody-mediated neutralization of flaviviruses: a reductionist view,” Virology, vol. 411, no. 2, pp. 306–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. A. K. I. Falconar, “Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines,” Clinical and Vaccine Immunology, vol. 15, no. 3, pp. 549–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Meyer, A. Banerjee, S. E. Frey, R. B. Belshe, and R. Ray, “A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection,” PLoS ONE, vol. 6, no. 8, Article ID e23699, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Burioni, R. A. Williamson, P. P. Sanna, F. E. Bloom, and D. R. Burton, “Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 1, pp. 355–359, 1994. View at Publisher · View at Google Scholar · View at Scopus
  73. M. S. Rolph, A. Zaid, N. E. Rulli, and S. Mahalingam, “Downregulation of interferon-β in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6,” Journal of Infectious Diseases, vol. 204, no. 3, pp. 489–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. S. S. Whitehead, J. E. Blaney, A. P. Durbin, and B. R. Murphy, “Prospects for a dengue virus vaccine,” Nature Reviews Microbiology, vol. 5, no. 7, pp. 518–528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. S.-M. Lok, V. Kostyuchenko, G. E. Nybakken et al., “Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins,” Nature Structural and Molecular Biology, vol. 15, no. 3, pp. 312–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. A. P. Goncalvez, R. Men, C. Wernly, R. H. Purcell, and C.-J. Lai, “Chimpanzee Fab fragments and a derived humanized immunogiobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses,” Journal of Virology, vol. 78, no. 23, pp. 12910–12918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. W. M. P. B. Wahala, A. A. Kraus, L. B. Haymore, M. A. Accavitti-Loper, and A. M. de Silva, “Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody,” Virology, vol. 392, no. 1, pp. 103–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. W. D. Crill, H. R. Hughes, M. J. Delorey, and G.-J. J. Chang, “Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens,” PLoS ONE, vol. 4, no. 4, Article ID e4991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Setthapramote, T. Sasaki, O. Puiprom et al., “Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection,” Biochemical and Biophysical Research Communications, vol. 423, no. 4, pp. 867–872, 2012.
  80. M. Beltramello, K. L. Williams, C. P. Simmons et al., “The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity,” Cell Host and Microbe, vol. 8, no. 3, pp. 271–283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. C. M. Midgley, M. Bajwa-Joseph, S. Vasanawathana et al., “An in-depth analysis of original antigenic sin in dengue virus infection,” Journal of Virology, vol. 85, no. 22, pp. 410–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Kaufmann, M. R. Vogt, J. Goudsmit et al., “Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 44, pp. 18950–18955, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Spurrier, J. M. Sampson, M. Totrov et al., “Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120,” Structure, vol. 19, no. 5, pp. 691–699, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. J. J. Schlesinger, M. W. Brandriss, and T. P. Monath, “Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein,” Virology, vol. 125, no. 1, pp. 8–17, 1983. View at Scopus
  85. M. W. Brandriss, J. J. Schlesinger, E. E. Walsh, and M. Briselli, “Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses,” Journal of General Virology, vol. 67, no. 2, pp. 229–234, 1986. View at Scopus
  86. H. Cho and M. S. Diamond, “Immune responses to West Nile virus infection in the central nervous system,” Viruses, vol. 4, no. 12, pp. 3812–3830, 2012.
  87. D. W. Beasley, A. D. Barrett, and R. B. Tesh, “Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done?” Antiviral Research, vol. 99, no. 1, pp. 1–5, 2013. View at Publisher · View at Google Scholar
  88. M. Throsby, J. Ter Meulen, C. Geuijen, J. Goudsmit, and J. De Kruif, “Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development,” Expert Review of Vaccines, vol. 6, no. 2, pp. 183–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. M. S. Diamond, T. G. Roberts, D. Edgil, B. Lu, J. Ernst, and E. Harris, “Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons,” Journal of Virology, vol. 74, no. 11, pp. 4957–4966, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. Z. Shimoni, M. J. Niven, S. Pitlick, and S. Bulvik, “Treatment of West Nile virus encephalitis with intravenous immunoglobulin,” Emerging Infectious Diseases, vol. 7, no. 4, article 759, 2001. View at Scopus
  91. A. Hamdan, P. Green, E. Mendelson, M. R. Kramer, S. Pitlik, and M. Weinberger, “Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis,” Transplant Infectious Disease, vol. 4, no. 3, pp. 160–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Haley, A. S. Retter, D. Fowler, J. Gea-Banacloche, and N. P. O'Grady, “The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis,” Clinical Infectious Diseases, vol. 37, no. 6, pp. e88–e90, 2003. View at Scopus
  93. K. M. Chung, G. E. Nybakken, B. S. Thompson et al., “Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc γ receptor-dependent and -independent mechanisms,” Journal of Virology, vol. 80, no. 3, pp. 1340–1351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. E. A. Henchal, L. S. Henchal, and J. J. Schlesinger, “Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus,” Journal of General Virology, vol. 69, no. 8, pp. 2101–2107, 1988. View at Scopus
  95. J. T. Roehrig, “Antigenic structure of flavivirus proteins,” Advances in Virus Research, vol. 59, pp. 141–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. M. D. Sánchez, T. C. Pierson, D. McAllister et al., “Characterization of neutralizing antibodies to West Nile virus,” Virology, vol. 336, no. 1, pp. 70–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. J. H. Beigel, J. L. Nordstrom, S. R. Pillemer et al., “Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2431–2436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. C. A. Smeraski, V. Siddharthan, and J. D. Morrey, “Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1,” Antiviral Research, vol. 91, no. 1, pp. 43–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Lelli, A. Moreno, E. Brocchi et al., “West Nile virus: characterization and diagnostic applications of monoclonal antibodies,” Virology Journal, vol. 9, article 81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. T. S. Gritsun, V. A. Lashkevich, and E. A. Gould, “Tick-borne encephalitis,” Antiviral Research, vol. 57, no. 1-2, pp. 129–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Růžek, T. S. Gritsun, N. L. Forrester et al., “Mutations in the NS2B and NS3 genes affect mouse neuroinvasiveness of a Western European field strain of tick-borne encephalitis virus,” Virology, vol. 374, no. 2, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Ecker, S. L. Allison, T. Meixner, and F. X. Heinz, “Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia,” Journal of General Virology, vol. 80, no. 1, pp. 179–185, 1999. View at Scopus
  103. H. Holzmann, M. S. Vorobyova, I. P. Ladyzhenskaya et al., “Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes,” Vaccine, vol. 10, no. 5, pp. 345–349, 1992. View at Publisher · View at Google Scholar · View at Scopus
  104. C. W. Mandl, “Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis,” Virus Research, vol. 111, no. 2, pp. 161–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. A. V. Atrasheuskaya, T. M. Fredeking, and G. M. Ignatyev, “Changes in immune parameters and their correction in human cases of tick-borne encephalitis,” Clinical and Experimental Immunology, vol. 131, no. 1, pp. 148–154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. K. L. Mansfield, N. Johnson, L. P. Phipps, J. R. Stephenson, A. R. Fooks, and T. Solomon, “Tick-borne encephalitis virus—a review of an emerging zoonosis,” Journal of General Virology, vol. 90, no. 8, pp. 1781–1794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. D. W. Vaughn and C. H. Hoke Jr., “The epidemiology of Japanese encephalitis: prospects for prevention,” Epidemiologic Reviews, vol. 14, pp. 197–221, 1992. View at Scopus
  108. T. Solomon, H. Ni, D. W. C. Beasley, M. Ekkelenkamp, M. J. Cardosa, and A. D. T. Barrett, “Origin and evolution of Japanese encephalitis virus in Southeast Asia,” Journal of Virology, vol. 77, no. 5, pp. 3091–3098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. M. R. Wilson, “Emerging viral infections,” Current Opinion in Neurology, vol. 26, no. 3, pp. 301–306, 2013.
  110. J. N. Hanna, S. A. Ritchie, D. A. Phillips et al., “An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995,” Medical Journal of Australia, vol. 165, no. 5, pp. 256–260, 1996. View at Scopus
  111. J. N. Hanna, S. A. Ritchie, D. A. Phillips et al., “Japanese encephalitis in north Queensland, Australia, 1998,” Medical Journal of Australia, vol. 170, no. 11, pp. 533–536, 1999. View at Scopus
  112. S. George, M. Gourie-Devi, and J. A. Rao, “Isolation of West Nile virus from the brains of children who had died of encephalitis,” Bulletin of the World Health Organization, vol. 62, no. 6, pp. 879–882, 1984. View at Scopus
  113. A. K. Gupta, A. A. Koshy, and V. J. Lad, “Enhanced protection of mice against Japanese encephalitis virus infection by combinations of monoclonal antibodies to glycoprotein E,” Acta Virologica, vol. 55, no. 2, pp. 165–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. T. H. Lee, B.-H. Song, S.-I. Yun et al., “A cross-protective mAb recognizes a novel epitope within the flavivirus NS1 protein,” Journal of General Virology, vol. 93, no. 1, pp. 20–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S. C. Weaver, “Host range, amplification and arboviral disease emergence,” Archives of Virology. Supplementum, no. 19, pp. 33–44, 2005. View at Scopus
  116. M. Solignat, B. Gay, S. Higgs, L. Briant, and C. Devaux, “Replication cycle of chikungunya: a re-emerging arbovirus,” Virology, vol. 393, no. 2, pp. 183–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. O. Schwartz and M. L. Albert, “Biology and pathogenesis of chikungunya virus,” Nature Reviews Microbiology, vol. 8, no. 7, pp. 491–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. W. Akahata, Z.-Y. Yang, H. Andersen et al., “A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection,” Nature Medicine, vol. 16, no. 3, pp. 334–338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Kielian and A. Helenius, “pH-Iinduced alterations in the fusogenic spike protein of Semliki Forest virus,” Journal of Cell Biology, vol. 101, no. 6, pp. 2284–2291, 1985. View at Scopus
  120. J. White and A. Helenius, “pH-Dependent fusion between the Semliki Forest virus membrane and liposomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 6, pp. 3273–3277, 1980. View at Scopus
  121. J. Dubuisson and C. M. Rice, “Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells,” Journal of Virology, vol. 67, no. 6, pp. 3363–3374, 1993. View at Scopus
  122. C. Y. Lee, Y.-W. Kam, J. Fric et al., “Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants,” PLoS Pathogens, vol. 7, no. 12, Article ID e1002390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. J. E. Voss, M.-C. Vaney, S. Duquerroy et al., “Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography,” Nature, vol. 468, no. 7324, pp. 709–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Li, J. Jose, Y. Xiang, R. J. Kuhn, and M. G. Rossmann, “Structural changes of envelope proteins during alphavirus fusion,” Nature, vol. 468, no. 7324, pp. 705–708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Fric, S. Bertin-Maghit, C. I. Wang, A. Nardin, and L. Warter, “Use of human monoclonal antibodies to treat Chikungunya virus infection,” Journal of Infectious Diseases, vol. 207, no. 2, pp. 319–322, 2013.
  126. P. V. Aguilar, J. G. Estrada-Franco, R. Navarro-Lopez, C. Ferro, A. D. Haddow, and S. C. Weaver, “Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella,” Future Virology, vol. 6, no. 6, pp. 721–740, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. S. C. Weaver, R. Winegar, I. D. Manger, and N. L. Forrester, “Alphaviruses: population genetics and determinants of emergence,” Antiviral Research, vol. 94, no. 3, pp. 242–257, 2012.
  128. S. Paessler and S. C. Weaver, “Vaccines for Venezuelan equine encephalitis,” Vaccine, vol. 27, no. 4, pp. D80–D85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. R. J. Phillpotts, “Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III,” Virus Research, vol. 120, no. 1-2, pp. 107–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. R. J. Phillpotts, L. D. Jones, and S. C. Howard, “Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus,” Vaccine, vol. 20, no. 11-12, pp. 1497–1504, 2002. View at Publisher · View at Google Scholar · View at Scopus
  131. J. H. Mathews, J. T. Roehrig, and D. W. Trent, “Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies,” Journal of Virology, vol. 55, no. 3, pp. 594–600, 1985. View at Scopus
  132. L. M. O'Brien, C. D. Underwood-Fowler, S. A. Goodchild, A. L. Phelps, and R. J. Phillpotts, “Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains,” Virology Journal, vol. 6, article 206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. L. M. O'Brien, S. A. Goodchild, R. J. Phillpotts, and S. D. Perkins, “A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48h after airborne challenge,” Virology, vol. 426, no. 2, pp. 100–105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. N. Clementi, N. Mancini, L. Solforosi, M. Castelli, M. Clementi, and R. Burioni, “Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens,” International Journal of Molecular Sciences, vol. 13, no. 7, pp. 8273–8292, 2012.
  135. A. R. Hunt, R. A. Bowen, S. Frederickson, T. Maruyama, J. T. Roehrig, and C. D. Blair, “Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection,” Virology, vol. 414, no. 2, pp. 146–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. W.-G. Hu, A. L. Phelps, S. Jager et al., “A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus,” Vaccine, vol. 28, no. 34, pp. 5558–5564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. T. Rulker, L. Voss, P. Thullier et al., “Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo,” PLoS ONE, vol. 7, no. 5, Article ID e37242, 2012.
  138. C. T. Walter and J. N. Barr, “Recent advances in the molecular and cellular biology of bunyaviruses,” Journal of General Virology, vol. 92, no. 11, pp. 2467–2484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. C. A. Whitehouse, “Crimean-Congo hemorrhagic fever,” Antiviral Research, vol. 64, no. 3, pp. 145–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Mertens, K. Schmidt, A. Ozkul, and M. H. Groschup, “The impact of Crimean-Congo hemorrhagic fever virus on public health,” Antiviral Research, vol. 98, no. 2, pp. 248–260, 2013.
  141. A. A. Ahmed, J. M. McFalls, C. Hoffmann et al., “Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus,” Journal of General Virology, vol. 86, no. 12, pp. 3327–3336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. R. Hewson, A. Gmyl, L. Gmyl et al., “Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus,” Journal of General Virology, vol. 85, no. 10, pp. 3059–3070, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. N. K. Blackburn, T. G. Besselaar, A. J. Shepherd, and R. Swanepoel, “Preparation and use of monoclonal antibodies for identifying Crimean-Congo hemorrhagic fever virus,” American Journal of Tropical Medicine and Hygiene, vol. 37, no. 2, pp. 392–397, 1987. View at Scopus
  144. T. Ikegami, “Molecular biology and genetic diversity of Rift Valley fever virus,” Antiviral Research, vol. 95, no. 3, pp. 293–310, 2012.
  145. K. Keegan and M. S. Collett, “Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus,” Journal of Virology, vol. 58, no. 2, pp. 263–270, 1986. View at Scopus
  146. T. G. Besselaar and N. K. Blackburn, “Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies,” Archives of Virology, vol. 121, no. 1–4, pp. 111–124, 1991. View at Publisher · View at Google Scholar · View at Scopus
  147. L. G. Presta, “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Advanced Drug Delivery Reviews, vol. 58, no. 5-6, pp. 640–656, 2006. View at Publisher · View at Google Scholar · View at Scopus